Assessment of the contribution of pharmacogenetics in overall treatment efficacy against malaria by DNA chip technology

Full Title Assessment of the contribution of pharmacogenetics in overall  treatment efficacy against malaria by DNA chip technology: An aid for the selection of appropriate drugs in malaria endemic areas.  Short Title  Project Leader Kefas Mugittu  Description Parasite resistance to antimalarials drugs has always been considered as the main contributor to treatment failure.  Although host factors, such as level of pre-existing immunity and adherence, have also been recognized as important factors of treatment success, almost no research has been conducted on the role of human host genetics in treatment outcome.  Inter-individual variability in drug response is partly attributed to differences in drug metabolizing enzymes, due to single point mutations, mainly members of the Cytochrome P450 (CYP) superfamily, and transporters.  We propose here to estimate the contribution of pharmacogenetics in overall treatment efficacy, using an extension of the DNA chip technology that we developed to monitor molecular markers of parasite resistance to drugs.  The Tanzanian component is part of a multi-country assessment (other site in Cambodia and Papua New Guinea).  Collaborators Blaise Genton                    Source of funding  Start Date                                      End Date

More info/ Relevant Docs